TriSalus Life Sciences, Inc. (NASDAQ:TLSI – Get Free Report) Director Mats Wahlstrom bought 50,000 shares of the business’s stock in a transaction on Thursday, November 12th. The stock was bought at an average cost of $2.24 per share, with a total value of $112,000.00. Following the completion of the purchase, the director directly owned 197,555 shares in the company, valued at approximately $442,523.20. The trade was a 33.89% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
TriSalus Life Sciences Stock Performance
Shares of TLSI stock opened at $2.43 on Monday. The company has a current ratio of 4.22, a quick ratio of 3.86 and a debt-to-equity ratio of 47.60. TriSalus Life Sciences, Inc. has a twelve month low of $2.20 and a twelve month high of $7.95. The company’s 50-day moving average price is $4.05 and its 200-day moving average price is $4.29. The stock has a market cap of $149.63 million, a price-to-earnings ratio of -4.96 and a beta of 0.50.
TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $12.88 million for the quarter, compared to the consensus estimate of $14.02 million. As a group, equities analysts predict that TriSalus Life Sciences, Inc. will post -0.62 earnings per share for the current year.
Analyst Upgrades and Downgrades
View Our Latest Research Report on TLSI
Institutional Investors Weigh In On TriSalus Life Sciences
Institutional investors have recently modified their holdings of the company. Cura Wealth Advisors LLC acquired a new position in shares of TriSalus Life Sciences during the 2nd quarter worth about $36,000. Russell Investments Group Ltd. acquired a new stake in shares of TriSalus Life Sciences during the 3rd quarter worth about $68,000. Provenance Wealth Advisors LLC purchased a new stake in TriSalus Life Sciences during the third quarter worth approximately $94,000. Renaissance Technologies LLC purchased a new stake in TriSalus Life Sciences during the first quarter worth approximately $124,000. Finally, Deutsche Bank AG acquired a new position in TriSalus Life Sciences in the second quarter valued at approximately $221,000. 2.58% of the stock is owned by hedge funds and other institutional investors.
About TriSalus Life Sciences
TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company’s TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.
Read More
- Five stocks we like better than TriSalus Life Sciences
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
